Dynamic observation of experimental autoimmune hepatitis in mice

World Chinese Journal of Digestology

Volumn 9, Issue 2, 2001, Pages 153-156

  Ma, X ^a   De Kai Qiu, ^a   Yan Shen Peng, ^a   En Ling Li, ^a   Xiao Yu Chen, ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Autoantigens; Autoimmune diseases; Experimental autoimmune hepatitis; Hepatitis immunology; Mice; Serodiagnosis

Indexed keywords

ALANINE AMINOTRANSFERASE; AUTOANTIGEN; FREUND ADJUVANT; PROTEIN S 100;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; EMULSION; INFLAMMATORY INFILTRATE; LIVER HISTOLOGY; LIVER INJURY; LYMPHOCYTE PROLIFERATION; NONHUMAN; T LYMPHOCYTE;

EID: 0035117715     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. The relationship between autoimmune markers and different clinical syndrome in autoimmune hepatitis
2. Recent developments in autoimmune liver disease
3. Autoimmune hepatitis: Evolving concepts and treatment strategies
4. Autoimmune hepatitis
5. Autoimmune hepatitis
6. Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture, Japan
7. Meeting report: International autoimmune hepatitis group
8. Toward diagnostic criteria for autoimmune hepatitis
9. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis
10. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis
11. A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1
12. Target proteins in human autoimmunity: Cytochromes P450 and UDP-glucuronosyltransferases
13. Antibodies to soluble liver antigen: Specific marker of autoimmune hepatitis
14. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis
15. Glutathione S-transferase as a major autoantigen in anti-SLA-positive autoimmune hepatitis
16. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis
17. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2
18. Serum soluble HLA-DR antigens in autoimmune hepatitis
19. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis
20. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis
21. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis
22. Increased bcl-2 expression in lymphocytes and its association with hepatocellular damage in patients with autoimmune hepatitis
23. T cell repertoire in the liver of patients with autoimmune hepatitis
24. Experimental models of autoimmune hepatitis
25. Establishment of experimental autoimmune hepatitis model in rats
26. Murine experimental autoimmune hepatitis: Nonspecific inflammation due to adjuvant oil
27. Experimental autoimmune hepatitis in mice following immunization with syngeneic liver proteins
28. Experimental autoimmune hepatitis: Disease induction, time course and T-cell reactivity
29. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression
30. Evidence for spontaneous immunosuppression in autoimmune hepatitis
31. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis
32. Requirement of IL-4 and liver NK1 + T cells for concanavalin A-induced hepatic injury in mice
33. Role of sinusoidal endothelial cells of the liver in concanavalin A-induced hepatic injury in mice
34. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism
35. Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene
36. Autoimmune hepatitis: The investigational and clinical challenges
37. Towards the pathogenesis of autoimmune liver disease
38. Circulating immune complex in murine autoimmune hepatitis
39. Autoantibodies in experimental autoimmune hepatitis
40. Immunohistopathological reactions for liver-specific membrane lipo-protein in experimental autoimmune hepatitis
41. Drug therapy in the management of type 1 autoimmune hepatitis
42. Prednisone withdrawal advocates: Beware of recurrent autoimmune hepatitis
43. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis
44. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial
45. Liver transplantation for autoimmune hepatitis: A long-term pathologic study
46. Liver transplantation for autoimmune hepatitis: Rejection and recurrence
47. Non-peptidic analogs of the cell adhesion motif RGD prevent experimental liver injury
48. Remission of experimental autoimmune hepatitis is associated with antigen-specific and non-specific immunosuppression
49. The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury
50. Protective effects of FUT-175 on acute massive hepatic necrosis induced in mice following endotoxin injection and immunization with liver proteins